These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38932114)

  • 1. Respiratory Syncytial Virus Vaccine Design Using Structure-Based Machine-Learning Models.
    McCarty TC; Vaisman II
    Viruses; 2024 May; 16(6):. PubMed ID: 38932114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
    Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The non-structural proteins of RSV: targeting interferon antagonists for vaccine development.
    Teng MN
    Infect Disord Drug Targets; 2012 Apr; 12(2):129-37. PubMed ID: 22335499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters.
    Levy M; Chen JW; Kaiser JA; Park HS; Liu X; Yang L; Santos C; Buchholz UJ; Le Nouën C
    PLoS Pathog; 2024 May; 20(5):e1012198. PubMed ID: 38739647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Respiratory Syncytial Virus Nonstructural Protein 2 Residues Essential for Exploitation of the Host Ubiquitin System and Inhibition of Innate Immune Responses.
    Whelan JN; Tran KC; van Rossum DB; Teng MN
    J Virol; 2016 Jul; 90(14):6453-6463. PubMed ID: 27147743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.
    Luongo C; Winter CC; Collins PL; Buchholz UJ
    J Virol; 2013 Feb; 87(4):1985-96. PubMed ID: 23236065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Perlowski C; Libous J; Oliva J; Jean-Philippe P; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Cielo M; Wiznia A; Deville JG; Yang L; Luongo C; Collins PL; Buchholz UJ
    J Infect Dis; 2020 Jun; 221(12):2050-2059. PubMed ID: 32006006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
    Luongo C; Yang L; Winter CC; Spann KM; Murphy BR; Collins PL; Buchholz UJ
    Vaccine; 2009 Sep; 27(41):5667-76. PubMed ID: 19646406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes.
    Meng J; Lee S; Hotard AL; Moore ML
    mBio; 2014 Sep; 5(5):e01704-14. PubMed ID: 25249281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation.
    Stobart CC; Rostad CA; Ke Z; Dillard RS; Hampton CM; Strauss JD; Yi H; Hotard AL; Meng J; Pickles RJ; Sakamoto K; Lee S; Currier MG; Moin SM; Graham BS; Boukhvalova MS; Gilbert BE; Blanco JC; Piedra PA; Wright ER; Moore ML
    Nat Commun; 2016 Dec; 7():13916. PubMed ID: 28000669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
    Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ
    J Virol; 2017 May; 91(10):. PubMed ID: 28275196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
    Luongo C; Winter CC; Collins PL; Buchholz UJ
    J Virol; 2012 Oct; 86(19):10792-804. PubMed ID: 22837193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Libous J; Perlowski C; Thumar B; Gnanashanmugam D; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Spector SA; Aziz M; Cielo M; Beneri C; Wiznia A; Luongo C; Collins P; Buchholz UJ
    J Infect Dis; 2020 Feb; 221(4):534-543. PubMed ID: 31758177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.
    Collins PL; Murphy BR
    Proc Am Thorac Soc; 2005; 2(2):166-73. PubMed ID: 16113487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates.
    Jin H; Cheng X; Traina-Dorge VL; Park HJ; Zhou H; Soike K; Kemble G
    Vaccine; 2003 Sep; 21(25-26):3647-52. PubMed ID: 12922094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.